HIV protease mutations associated with amprenavir resistance during salvage therapy

Importance of I54M

Melissa D. Murphy, Gail I. Marousek, Sunwen Chou

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir. Study design: Serial plasma HIV loads and protease gene mutations were monitored in 31 patients who received amprenavir, including 19 who had been exposed to other protease inhibitors (salvage therapy). Recombinant phenotyping was used to assess the significance of new mutations appearing after amprenavir therapy. Results: After 6-8 months of amprenavir, 4 treatment-naïve and 5 salvage patients had an undetectable plasma HIV load, while 12 other salvage patients showed less than 10-fold HIV load reduction. HIV protease mutations associated with amprenavir resistance included I84V, I50V, I47V, V32I, and I54M. Among mutations newly detected after amprenavir treatment, I54M occurred in six cases, I54L in two cases, M46I in two cases, I47V in one case and I50V in one case. When compared with pretreatment plasma without the mutation, recombinant phenotyping showed that I54M increased the amprenavir resistance by at least 6-fold, resulting in up to 48-fold resistance over a drug-sensitive control. Conclusions: Protease I54M frequently appears after amprenavir therapy, and when combined with pre-existing mutations, leads to high-level amprenavir resistance and treatment failure.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
JournalJournal of Clinical Virology
Volume30
Issue number1
DOIs
StatePublished - May 2004

Fingerprint

HIV Protease
Salvage Therapy
Mutation
HIV
Therapeutics
amprenavir
Drug and Narcotic Control
Protease Inhibitors
Treatment Failure
Peptide Hydrolases

Keywords

  • Amprenavir
  • HIV
  • Resistance mutations

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

HIV protease mutations associated with amprenavir resistance during salvage therapy : Importance of I54M. / Murphy, Melissa D.; Marousek, Gail I.; Chou, Sunwen.

In: Journal of Clinical Virology, Vol. 30, No. 1, 05.2004, p. 62-67.

Research output: Contribution to journalArticle

@article{5c5cb862b9d04a38acdab802bf1b5975,
title = "HIV protease mutations associated with amprenavir resistance during salvage therapy: Importance of I54M",
abstract = "Objective: To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir. Study design: Serial plasma HIV loads and protease gene mutations were monitored in 31 patients who received amprenavir, including 19 who had been exposed to other protease inhibitors (salvage therapy). Recombinant phenotyping was used to assess the significance of new mutations appearing after amprenavir therapy. Results: After 6-8 months of amprenavir, 4 treatment-na{\"i}ve and 5 salvage patients had an undetectable plasma HIV load, while 12 other salvage patients showed less than 10-fold HIV load reduction. HIV protease mutations associated with amprenavir resistance included I84V, I50V, I47V, V32I, and I54M. Among mutations newly detected after amprenavir treatment, I54M occurred in six cases, I54L in two cases, M46I in two cases, I47V in one case and I50V in one case. When compared with pretreatment plasma without the mutation, recombinant phenotyping showed that I54M increased the amprenavir resistance by at least 6-fold, resulting in up to 48-fold resistance over a drug-sensitive control. Conclusions: Protease I54M frequently appears after amprenavir therapy, and when combined with pre-existing mutations, leads to high-level amprenavir resistance and treatment failure.",
keywords = "Amprenavir, HIV, Resistance mutations",
author = "Murphy, {Melissa D.} and Marousek, {Gail I.} and Sunwen Chou",
year = "2004",
month = "5",
doi = "10.1016/j.jcv.2003.08.013",
language = "English (US)",
volume = "30",
pages = "62--67",
journal = "Journal of Clinical Virology",
issn = "1386-6532",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - HIV protease mutations associated with amprenavir resistance during salvage therapy

T2 - Importance of I54M

AU - Murphy, Melissa D.

AU - Marousek, Gail I.

AU - Chou, Sunwen

PY - 2004/5

Y1 - 2004/5

N2 - Objective: To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir. Study design: Serial plasma HIV loads and protease gene mutations were monitored in 31 patients who received amprenavir, including 19 who had been exposed to other protease inhibitors (salvage therapy). Recombinant phenotyping was used to assess the significance of new mutations appearing after amprenavir therapy. Results: After 6-8 months of amprenavir, 4 treatment-naïve and 5 salvage patients had an undetectable plasma HIV load, while 12 other salvage patients showed less than 10-fold HIV load reduction. HIV protease mutations associated with amprenavir resistance included I84V, I50V, I47V, V32I, and I54M. Among mutations newly detected after amprenavir treatment, I54M occurred in six cases, I54L in two cases, M46I in two cases, I47V in one case and I50V in one case. When compared with pretreatment plasma without the mutation, recombinant phenotyping showed that I54M increased the amprenavir resistance by at least 6-fold, resulting in up to 48-fold resistance over a drug-sensitive control. Conclusions: Protease I54M frequently appears after amprenavir therapy, and when combined with pre-existing mutations, leads to high-level amprenavir resistance and treatment failure.

AB - Objective: To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir. Study design: Serial plasma HIV loads and protease gene mutations were monitored in 31 patients who received amprenavir, including 19 who had been exposed to other protease inhibitors (salvage therapy). Recombinant phenotyping was used to assess the significance of new mutations appearing after amprenavir therapy. Results: After 6-8 months of amprenavir, 4 treatment-naïve and 5 salvage patients had an undetectable plasma HIV load, while 12 other salvage patients showed less than 10-fold HIV load reduction. HIV protease mutations associated with amprenavir resistance included I84V, I50V, I47V, V32I, and I54M. Among mutations newly detected after amprenavir treatment, I54M occurred in six cases, I54L in two cases, M46I in two cases, I47V in one case and I50V in one case. When compared with pretreatment plasma without the mutation, recombinant phenotyping showed that I54M increased the amprenavir resistance by at least 6-fold, resulting in up to 48-fold resistance over a drug-sensitive control. Conclusions: Protease I54M frequently appears after amprenavir therapy, and when combined with pre-existing mutations, leads to high-level amprenavir resistance and treatment failure.

KW - Amprenavir

KW - HIV

KW - Resistance mutations

UR - http://www.scopus.com/inward/record.url?scp=1842608902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842608902&partnerID=8YFLogxK

U2 - 10.1016/j.jcv.2003.08.013

DO - 10.1016/j.jcv.2003.08.013

M3 - Article

VL - 30

SP - 62

EP - 67

JO - Journal of Clinical Virology

JF - Journal of Clinical Virology

SN - 1386-6532

IS - 1

ER -